Genmab A/S Files Form 6-K for SEC Reporting
Ticker: GNMSF · Form: 6-K · Filed: May 13, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | May 13, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, compliance
TL;DR
Genmab A/S filed a 6-K, standard SEC paperwork, no new info.
AI Summary
Genmab A/S filed a Form 6-K on May 13, 2024, to be incorporated by reference into its existing S-8 registration statements. The filing does not contain new financial data or operational updates but serves as a procedural document for SEC reporting requirements.
Why It Matters
This filing is a routine SEC submission for foreign private issuers, indicating ongoing compliance with reporting obligations rather than a material event.
Risk Assessment
Risk Level: low — This is a routine administrative filing with the SEC and does not contain new material information that would impact the company's risk profile.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-007890 (filing_id) — Accession Number
- 20240513 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Form S-8 (document) — Incorporated by Reference
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K filing is to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970 and 333-277273).
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on May 13, 2024.
What type of company is Genmab A/S?
Genmab A/S is identified as a foreign private issuer and its Standard Industrial Classification is Pharmaceutical Preparations [2834].
Does this filing contain new financial results for Genmab A/S?
No, this filing is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 and does not appear to contain new financial results.
What is the principal executive office address for Genmab A/S?
The address of the principal executive offices for Genmab A/S is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 236 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2024-05-13 11:29:14
Filing Documents
- tmb-20240513x6k.htm (6-K) — 19KB
- tmb-20240513xex99d1.htm (EX-99.1) — 65KB
- tmb-20240513xex99d1a.htm (EX-99.1(A)) — 26KB
- tmb-20240513xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240513xex99d1a001.jpg (GRAPHIC) — 5KB
- 0001558370-24-007890.txt ( ) — 124KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: MAY 13, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated May 13, 2024: Transactions in Connection with Share Buy-back Program 99.1(a) Appendix Share buyback program – Specification for May 6 – May 10, 2024